EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Beyond Weight Loss: Metabolic and Immunologic Power of GLP-1 Agonists in Plastic Surgery

Niki K Patel iD, Tatiana Henriksson, Anna Sidhu, Katherine H Carruthers, Kerri Woodberry

Aesthetic Surgery Journal · 16.06.2026 · 46 (7) · 753-758

DOI: 10.1093/asj/sjag064 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Aesthetic Surgery Journal, online erschienen am 30.03.2026. Verfasst von Niki K Patel und 4 weiteren Autor:innen. Hauptthemen laut MEDLINE: Glucagon-Like Peptide-1 Receptor Agonists, Diabetes Mellitus, Type 2, Obesity, Plastic Surgery Procedures. Die Arbeit nennt 27 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are widely used for glycemic control and weight management in patients with type 2 diabetes and obesity, and their use has become increasingly common among candidates for elective plastic surgery. As a result, plastic surgeons are frequently encountering patients receiving GLP-1 RA therapy in the setting of metabolic and inflammatory comorbidities that may influence perioperative risk. This focused review examines the existing literature on GLP-1 RAs and contextualizes their biologic effects with considerations relevant to elective plastic surgery. A review of studies identified through PubMed, MEDLINE, and ClinicalKey was performed, with emphasis on the effects of GLP-1 RAs on chronic inflammation, immune signaling, endothelial function, and tissue biology in populations with metabolic or inflammatory disease. Across preclinical and clinical studies, GLP-1 RAs have been associated with attenuation of chronic inflammatory signaling, including reductions in circulating inflammatory markers and modulation of immune cell activity. Clinical benefits have been reported in conditions frequently encountered in plastic surgery practice, such as metabolic syndrome, polycystic ovary syndrome, and inflammatory skin diseases; however, direct evidence evaluating postoperative outcomes in surgical populations remains limited. Rather than acting on the acute postoperative healing response, GLP-1 RAs primarily influence chronic metabolic and inflammatory disease states that contribute to surgical risk. Understanding these effects may assist plastic surgeons in the perioperative setting, as GLP-1 RA therapy becomes increasingly prevalent in elective practice. Level of Evidence: 3 (Therapeutic)

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Glucagon-Like Peptide-1 Receptor AgonistsDiabetes Mellitus, Type 2ObesityPlastic Surgery ProceduresHumansWeight LossInflammationGlucagon-Like Peptide-1 ReceptorAnimals

Substanzen

Glucagon-Like Peptide-1 Receptor AgonistsGlucagon-Like Peptide-1 Receptor

Autor:innen und Institutionen

ORCID-Profile: Niki K Patel

Zitieren

APA

Patel, N. K., Henriksson, T., Sidhu, A., Carruthers, K. H., & Woodberry, K. (2026). Beyond Weight Loss: Metabolic and Immunologic Power of GLP-1 Agonists in Plastic Surgery. Aesthetic Surgery Journal, 46(7), 753-758. https://doi.org/10.1093/asj/sjag064

Vancouver

Patel NK, Henriksson T, Sidhu A, Carruthers KH, Woodberry K. Beyond Weight Loss: Metabolic and Immunologic Power of GLP-1 Agonists in Plastic Surgery. Aesthetic Surgery Journal. 2026;46(7):753-758. doi:10.1093/asj/sjag064

BibTeX
@article{Patel2026,
  author = {Patel, Niki K and Henriksson, Tatiana and Sidhu, Anna and Carruthers, Katherine H and Woodberry, Kerri},
  title = {Beyond Weight Loss: Metabolic and Immunologic Power of GLP-1 Agonists in Plastic Surgery},
  journal = {Aesthetic Surgery Journal},
  year = {2026},
  volume = {46},
  number = {7},
  pages = {753--758},
  doi = {10.1093/asj/sjag064}
}
Kostenlos starten →